Consonance Capital Partners

Consonance Capital Partners (“CCP”) is a private equity manager focused exclusively on investing in the healthcare industry. CCP’s founders, Mitchell Blutt, MD, Benjamin Edmands, Stephen McKenna, and Nancy-Ann DeParle, partnered together for over a decade while at JPMorgan Partners and its successor and predecessor entities (collectively “JPMP”), and have over 90 years of combined experience in private equity investing, primarily within healthcare. To date, CCP has raised over $1.3 billion in equity capital across two funds, and CCP is currently investing out of Consonance Private Equity II, L.P. Consonance Capital Partners (“CCP”) seeks to invest in U.S. middle-market companies that add sustainable value to the healthcare system via the delivery of higher-quality care at a lower cost. The firm's strategy is to leverage its network and experience developed over decades in the healthcare industry to proactively identify high-growth industry subsectors, proven business models in emerging subsectors, and platform opportunities in unconsolidated subsectors. The team at CCP then systematically pursues opportunities within this framework that meet its core investment criteria. Key to the process is the identification of management teams that have a demonstrated ability to effectively navigate a highly complex and regulated industry. CCP deeply values these partnerships and believes that strong operators with aligned incentives are the backbone of a successful investment strategy. CCP targets growth equity, leveraged buyouts, and recapitalization transactions in the middle market. The team at CCP aims to target companies that have between $25 million and $500 million in revenues; the team is flexible to invest in companies outside of this range.